Success Metrics

Active Trials

1(33%)

Phase Distribution

Ph phase_2

33%

Ph phase_4

33%

Ph phase_1

33%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution3 total trials

Phase 1Safety & dosage

1(33.3%)

Phase 2Efficacy & side effects

1(33.3%)

Phase 4Post-market surveillance

1(33.3%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

0.0%

0 of 0 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Active(3)

Detailed Status

Not yet recruiting2

Recruiting1

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

N/A

Most Advanced

Phase 4

Trials by Phase

Phase 11 (33.3%)

Phase 21 (33.3%)

Phase 41 (33.3%)

Trials by Status

recruiting133%

not_yet_recruiting267%

Recent Activity

1 active trials

Showing 3 of 3

not_yet_recruitingphase_2

A Study on the First-line Treatment of Small Cell Lung Cancer With Adebrelimab and Vunakizumab and Chemotherapy

NCT07069270

recruitingphase_1

Vunakizumab for the Treatment of Mild to Moderate Systemic Lupus Erythematosus

NCT06881290

not_yet_recruitingphase_4

Phase IV Study: Vunakizumab Efficacy and Safety in Moderate-to-severe Plaque Psoriasis

NCT06779097

Clinical Trials (3)

Showing 3 of 3 trials

NCT07069270Phase 2

A Study on the First-line Treatment of Small Cell Lung Cancer With Adebrelimab and Vunakizumab and Chemotherapy

Not Yet Recruiting

NCT06881290Phase 1

Vunakizumab for the Treatment of Mild to Moderate Systemic Lupus Erythematosus

Recruiting

NCT06779097Phase 4

Phase IV Study: Vunakizumab Efficacy and Safety in Moderate-to-severe Plaque Psoriasis

Not Yet Recruiting

All 3 trials loaded

Drug Details

Intervention Type: DRUG
Total Trials: 3